Core Points - BioPorto A/S has completed a private placement of 40,438,426 new shares, raising approximately DKK 43 million in new capital [1][2] - The new shares represent 8.89% of BioPorto's registered share capital prior to the increase [2] - The nominal share capital of BioPorto now amounts to DKK 495,108,887, consisting of 495,108,887 shares [4] Company Overview - BioPorto is an in vitro diagnostics company focused on improving patient outcomes through actionable kidney biomarkers, particularly for Acute Kidney Injury (AKI) [5] - The company's flagship products utilize the NGAL biomarker to aid in the risk assessment and management of AKI, enabling earlier intervention [5] - BioPorto's tests are marketed under various registrations, including CE mark in several countries and FDA clearance for ProNephro AKI™ in the US [5] Trading and Listing - The new shares will be admitted to trading and officially listed on Nasdaq Copenhagen A/S under the company's permanent ISIN code [3] - The new shares carry the same rights as existing shares, including the right to receive dividends from the time the capital increase is registered [3] Capital Structure - Following the capital increase, BioPorto's Articles of Association have been updated to reflect the new share capital structure [4] - The company emphasizes its commitment to transparency and provides access to its announcements and relevant information through its investor relations platform [4]

Core Insights - BioPorto A/S has successfully completed a private placement, raising approximately DKK 43 million through the issuance of 40,438,426 new shares, which represents 8.89% of the company's registered share capital prior to the increase [1][2]. Group 1: Share Capital Increase - The capital increase has been registered with the Danish Business Authority, and the gross proceeds from the issue amount to approximately DKK 43 million [2]. - The new shares will carry the same rights as existing shares, including the right to receive dividends from the time the capital increase is registered [3]. Group 2: Company Overview - BioPorto is focused on in vitro diagnostics, particularly in developing kidney biomarkers to aid in the management of Acute Kidney Injury (AKI) [5]. - The company's flagship products utilize the NGAL biomarker, which allows for quicker identification of patients at risk of AKI, facilitating earlier intervention [5]. - BioPorto's shares are listed on the Nasdaq Copenhagen stock exchange, and the company has facilities in both Copenhagen, Denmark, and Boston, MA, USA [6].

Core Viewpoint - BioPorto A/S has successfully completed a private placement of 40,438,426 new shares, raising approximately DKK 43 million, which will enhance the company's financial flexibility to pursue strategic priorities and strengthen its commercial platform [1][2]. Group 1: Private Placement Details - The private placement involved 40,438,426 new shares and is expected to generate gross proceeds of around DKK 43 million [1][2]. - The subscription price for the new shares is scheduled to be paid by 24 November 2025, with the share capital increase registration to follow shortly thereafter [2]. - BioPorto anticipates that the new shares will be listed on Nasdaq Copenhagen A/S by no later than 26 November 2025 [2]. Group 2: Strategic Implications - The funds raised will support the completion of data collection, submission of a pre-submission to the FDA, and initiation of a Validation Study in the U.S. clinical trial [2]. - The Board of BioPorto has considered various future financing options, including potential divestments of non-core assets and credit facilities, to ensure a balanced funding structure [2]. - The company aims to position itself for positive cash flow by the second half of 2027 [2]. Group 3: Company Overview - BioPorto specializes in in vitro diagnostics, focusing on actionable kidney biomarkers to improve patient management and outcomes [4][5]. - The flagship products are based on the NGAL biomarker, which aids in the risk assessment and management of Acute Kidney Injury (AKI) [5]. - BioPorto's tests are marketed under various registrations, including CE mark and FDA clearance for ProNephro AKI™ in the U.S. [5].

Core Viewpoint - BioPorto A/S has initiated a pre-subscribed private placement of up to 40,438,426 new shares to support its financing strategy aimed at achieving positive cash flow by the second half of 2027 [3][4][5]. Financing Strategy - The company identified a funding need of DKK 60–70 million to complete a U.S. clinical study and strengthen its commercial platform [4]. - A variety of financing alternatives were evaluated, including equity issuance and strategic financing solutions, to support long-term growth [4]. Private Placement Details - The private placement is fully pre-subscribed, with indications for the entire amount, expected to raise approximately DKK 43 million [5][9]. - The subscription price is set at DKK 1.072, matching the closing price of BioPorto shares on Nasdaq Copenhagen on the announcement date [9]. Share Offering Terms - The offering includes up to 40,438,426 new shares, representing 8.89% of the company's registered share capital prior to the increase [8]. - The new shares will carry the same rights as existing shares and will be registered through VP Securities A/S [10]. Timeline and Trading - The subscription period has commenced and will close at short notice, with results to be announced shortly thereafter [12]. - New shares are expected to be listed on Nasdaq Copenhagen by November 26, 2025, subject to the offering not being withdrawn [13]. Company Overview - BioPorto specializes in in vitro diagnostics, focusing on actionable kidney biomarkers to improve patient management [15][16]. - The company's flagship products are based on the NGAL biomarker, aiding in the risk assessment and management of Acute Kidney Injury (AKI) [16].

Core Insights - BioPorto is actively participating in the Association for Diagnostics & Laboratory Medicine meeting, focusing on NGAL and Acute Kidney Injury (AKI) [1][4] - The conference highlights the importance of early detection of AKI, particularly in pediatric populations, using NGAL as a promising biomarker [2][4] - BioPorto's ProNephro AKI™ (NGAL) is FDA cleared for risk stratification of ICU patients aged 3 months to 21 years for moderate to severe AKI [4][11] Industry Focus - AKI remains a critical topic in laboratory medicine, especially with changes in eGFR calculations and the transition from AKI to Chronic Kidney Disease (CKD) [2] - The conference includes special sessions on next-generation biomarkers for early prediction and diagnosis of AKI, emphasizing the need for innovative diagnostic tools [3][2] - Ongoing interest in AKI is expected to continue into 2025 and 2026, driven by the KDIGO project to update AKI guidelines [6] Company Initiatives - BioPorto is promoting its NGAL tests to lab directors and clinical managers at the conference, aiming to enhance awareness and adoption of its products [4][7] - The company is engaging with worldwide partners to review collaborations and the business impact of its FDA cleared products [5] - BioPorto's focus on actionable biomarkers aims to improve clinical outcomes and patient management in AKI [10][11]